Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)

Bibliographic Details
Main Authors: Burmester, Gerd R, Feist, E, Kellner, H, Braun, J, Iking-Konert, C, Rubbert-Roth, A
Format: Online
Language:English
Published: BMJ Group 2010
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070275/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070275/

Similar Items